Products for Research Use Only

Olsalazine-d3

CAT: 0804-HY-B0174AS1Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0174AS1Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Olsalazine-d3 is deuterated labeled Olsalazine. Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic[1][2][3].
UNSPSC
12352005
Target
Apoptosis; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Others
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Solubility
10 mM in DMSO
Smiles
O=C(O)C1=C(O)C=CC(/N=N/C2=C([2H])C(C(O)=O)=C(O)C([2H])=C2[2H])=C1
Molecular Formula
C14H7D3N2O6
Molecular Weight
305.26
References & Citations
[1]Brown WA, et al. 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci. 2000 Aug;45 (8) :1578-84.|[2]Thapa D, et al. Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis. Int J Mol Sci. 2025 Aug 16;26 (16) :7913.|[3]Niu Y, et al. Olsalazine Sodium Increases Renal Urate Excretion by Modulating Urate Transporters in Hyperuricemic Animals. Biol Pharm Bull. 2020 Nov 1;43 (11) :1653-1659.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported